KB-1473

Zalutumumab

45756

Background of Zalutumumab

Zalutumumab (proposed trade name HuMax-EGFR) is a high-affinity, fully human IgG1 monoclonal antibody (mAb) targeting the epidermal growth factor receptor (EGFR), also known as ErbB1/HER1. Developed by Genmab, this antibody is designed for the treatment of squamous cell carcinoma of the head and neck (SCCHN), a specific type of cancer.Zalutumumab originates from transgenic mice immunized with A431-derived EGFR. In 2009, the U.S. Food and Drug Administration (FDA) granted Fast Track status to zalutumumab for patients with SCCHN who have failed standard therapies and have no other treatment options available.

Specifications

Catalog Number	KB-1473
Antibody Name	Zalutumumab
Isotype	Human IgG1,kappa
Target	EGFR
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	ELISA
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Lammerts van Bueren JJ, Bleeker WK, Brännström A, von Euler A, Jansson M, Peipp M, Schneider-Merck T, Valerius T, van de Winkel JG, Parren PW (April 2008). "The antibody zalutumumab inhibits epidermal growth factor receptor signaling by limiting intra- and intermolecular flexibility". Proceedings of the National Academy of Sciences of the United States of America. 105 (16): 6109–14.